Amgen Inc. and UCB Group have refiled the biologics license application (BLA) for their osteoporosis candidate Evenity (romosozumab) with a highly regarded study group’s review of the drug’s cardiovascular risk, hoping that will allay concerns that led to a complete response letter last July and which could limit the drug's competitive profile.
An evaluation of adverse event data by the Thrombosis in Myocardial Infarction (TIMI) study group at Brigham & Women’s Hospital is part of the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?